- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01723527
Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin
December 10, 2014 updated by: Anthony DeFulio, Johns Hopkins University
More Americans are arrested for drug offenses than for any other crime.
In 2009, over 294,000 arrests were made for possession of cocaine or heroin.
Incarceration does not address the root problems and is frequently followed by relapse and re-arrest after release.
In the case of opiate-dependent adults arrested for possession of heroin, one potentially effective alternative is to divert offenders to methadone maintenance treatment (MMT) as an alternative to adjudication of their case.
MMT is an effective treatment for heroin dependence, and appears very effective for criminal offenders.
However, cocaine use is common in MMT patients, including those with recent criminal justice involvement, and MMT alone is ineffective in addressing cocaine use.
Continued cocaine use carries a substantial health burden and necessarily entails continued criminal activity.
Thus, treatment for diverted opiate-dependent offenders should be designed to address cocaine use as well as opiate use.
A Stage 1 Behavior Therapy Development project is planned over 2 years to adapt, manualize and pilot test the Therapeutic Workplace intervention for adults charged with heroin possession and offered diversion to methadone maintenance treatment as an alternative to adjudication of their case.
The Therapeutic Workplace is a novel, employment-based contingency management intervention that has been very effective in promoting cocaine abstinence in adults who use cocaine persistently during methadone treatment.
In the Therapeutic Workplace, participants are hired in a model workplace and required to provide drug-free urine samples to work and to earn maximum pay.
Once we develop and manualize the adapted version of the Therapeutic Workplace for adults arrested for heroin possession, a pilot test will be conducted.
Individuals identified by the State Attorney's office as candidates for diversion will be assessed for study eligibility.
Given the high rates of injection drug use and injection-related transmission of HIV in Baltimore, this study will be restricted to injection drug users to evaluate the potential utility of this intervention in reducing HIV risk.
Eligible individuals will be offered methadone maintenance in lieu of prosecution and will be required to remain in methadone treatment for 90 days.
All participants will receive standard MMT, independent of whether they decide to participate in the pilot study.
After beginning MMT, participants will be invited to enroll in the pilot study and randomly assigned to two study groups.
Participants assigned to the Usual Care Diversion group will receive the standard MMT.
Participants assigned to the Therapeutic Workplace Enhanced Diversion group will receive the standard MMT and the Therapeutic Workplace intervention.
The data from this pilot study will serve as the foundation for a full-scaled randomized controlled trial.
Overall, the Therapeutic Workplace could serve as a novel and ideal intervention for many heroin dependent adults involved in the criminal justice system.
The use of MMT in lieu of adjudication in combination with the Therapeutic Workplace could increase drug abstinence and employment and decrease HIV risk and criminal activity in this refractory high-risk population.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Center for Learning and Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- report using heroin at least 20 of the last 30 days of living in the community
- meet criteria for methadone maintenance (at least one year of meeting DSM IV criteria for heroin dependence)
- have visible track marks or other clear physical evidence of injection drug use
- report using cocaine in the last 30 days
- were unemployed prior to arrest
- have a income below the federal poverty level
- live in the Baltimore City area
Exclusion Criteria:
- report current suicidal ideation or hallucinations
- receiving opioid pharmacotherapy prior to arrest
- have a serious uncontrolled medical condition that would prevent attendance in methadone or buprenorphine treatment
- are pregnant or breastfeeding
- have a physical imparement that would prevent typing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Therapeutic Workplace
Participants assigned to this condition will receive the standard services and requirements for diversion as described for the usual care group, and will also be eligible to attend the three-phase Therapeutic Workplace (TW) intervention.
All phases of this intervention include employment-based drug abstinence reinforcement contingencies.
Under these contingencies, participants can work and earn wages or wage subsidies contingent upon drug abstinence as verified by urinalysis.
Phase 1 of the TW intervention is expected to increase cocaine abstinence and to prepare participants for employment.
Phase 2 of the TW intervention is expected to maintain abstinence while participants are employed in an onsite model workplace.
Phase 3 is designed to increase employment in community jobs and to maintain abstinence while participants are employed in offsite community workplaces.
|
Clinic-Based Methadone Maintenance Treatment
Clinic-Based Buprenorphine Maintenance Treatment
Other Names:
|
Active Comparator: Diversion to treatment (Usual Care)
Participants in this condition will be offered the standard treatment services available in community methadone and buprenorphine programs, including medication (methadone or buprenorphine, respectively), counseling services, HIV testing, and case management.
All services will be provided in the treatment clinics.
There are a number of clinics within easy walking distance from the research site, and others throughout the city that are reachable by public transportation from the research site.
In addition, all participants will receive referrals to the Re-Entry Center, a One-Stop Career Center tailored to the needs of offenders, at all intake and monthly assessments.
As mentioned in detail above, participants will be required by the court to stay enrolled in treatment for 90 days.
It is important to note that all diverted individuals will receive these services and requirements, independent of whether they agree to participate in the pilot study.
|
Clinic-Based Methadone Maintenance Treatment
Clinic-Based Buprenorphine Maintenance Treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cocaine abstinence as assessed by urinalysis
Time Frame: One year
|
dichotomous (Y/N)
|
One year
|
Cocaine abstinence as assessed by self-reports
Time Frame: One year
|
dichotomous (Y/N)
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Any drug use (Y/N)
Time Frame: One year
|
Any drug use will be counted as Yes if a urine sample indicates that the participant is positive for any of the DOT 5 drugs, or if the participant reports using any of the DOT 5 drugs (Amphetamines, Cocaine, Marijuana, Opiates, PCP).
|
One year
|
Any engagement in HIV risk behavior (Y/N)
Time Frame: One year
|
Any engagement in HIV risk behavior will be counted as Yes if a participant reports any unprotected vaginal or anal sex or reports any injection drug use that includes the sharing of injection equipment.
|
One year
|
Any criminal activity (Y/N)
Time Frame: One year
|
Criminal activity will counted as Yes if a participant reports any days of illegal activity in the previous 30 days, or has been arrested for any new crime in the previous 30 days according to publically available records maintained by the Maryland DPSCS.
|
One year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Anthony DeFulio, Ph.D., Johns Hopkins University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2012
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
August 1, 2014
Study Registration Dates
First Submitted
November 6, 2012
First Submitted That Met QC Criteria
November 6, 2012
First Posted (Estimate)
November 8, 2012
Study Record Updates
Last Update Posted (Estimate)
December 11, 2014
Last Update Submitted That Met QC Criteria
December 10, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Narcotic-Related Disorders
- Opioid-Related Disorders
- Heroin Dependence
- Cocaine-Related Disorders
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Narcotic Antagonists
- Respiratory System Agents
- Antitussive Agents
- Buprenorphine
- Methadone
Other Study ID Numbers
- 1R34DA033510-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
-
National Taiwan UniversityRecruiting
Clinical Trials on Methadone
-
Pontificia Universidad Catolica de ChileCompletedPain, Postoperative | Opioid Use | Methadone Overdose of Undetermined IntentChile
-
Washington University School of MedicineCompleted
-
University of Southern DenmarkCompletedPain, Postoperative | Pain, Post Operative | Analgesics, Opioid | MethadoneDenmark
-
Washington University School of MedicineCompleted
-
The Miriam HospitalUnknownOpioid-Related DisordersUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingChronic Pain | Opioid Use Disorder | MethadoneUnited States
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS)WithdrawnPolyneuropathy | HIV-associated NeuropathyUnited States
-
Washington University School of MedicineCompleted
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedOpiate DependenceUnited States
-
University of VirginiaCompleted